MA33717B1 - Immunoconjugués ciblés - Google Patents

Immunoconjugués ciblés

Info

Publication number
MA33717B1
MA33717B1 MA34588A MA34588A MA33717B1 MA 33717 B1 MA33717 B1 MA 33717B1 MA 34588 A MA34588 A MA 34588A MA 34588 A MA34588 A MA 34588A MA 33717 B1 MA33717 B1 MA 33717B1
Authority
MA
Morocco
Prior art keywords
immunoconjugates
relates
present
nucleic acid
methods
Prior art date
Application number
MA34588A
Other languages
English (en)
Inventor
Ralf Hosse
Ekkehard Moessner
Michela Silacci-Melkko
Pablo Umana
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43033282&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33717(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA33717B1 publication Critical patent/MA33717B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des immunoconjugués. Selon des modes de réalisation particuliers, la présente invention porte sur des immunoconjugués comprenant au moins un fragment effecteur monocaténaire et deux fragments de liaison à l'antigène ou plus. De plus, la présente invention concerne des molécules d'acides nucléiques codant pour lesdits immunoconjugués, des vecteurs et des cellules hôtes comprenant lesdites molécules d'acides nucléiques. L'invention concerne également des procédés de production des immunoconjugués de l'invention et des procédés d'utilisation des immunoconjugués dans le traitement de maladies.
MA34588A 2009-08-17 2012-01-30 Immunoconjugués ciblés MA33717B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23458409P 2009-08-17 2009-08-17
EP10162410 2010-05-10
PCT/EP2010/061810 WO2011020783A2 (fr) 2009-08-17 2010-08-13 Immunoconjugués ciblés

Publications (1)

Publication Number Publication Date
MA33717B1 true MA33717B1 (fr) 2012-11-01

Family

ID=43033282

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34588A MA33717B1 (fr) 2009-08-17 2012-01-30 Immunoconjugués ciblés

Country Status (21)

Country Link
US (1) US8945571B2 (fr)
EP (1) EP2467165B1 (fr)
JP (1) JP5764127B2 (fr)
KR (2) KR101588598B1 (fr)
CN (1) CN102573922B (fr)
AR (1) AR077879A1 (fr)
AU (1) AU2010285071A1 (fr)
CA (1) CA2769619C (fr)
CO (1) CO6430436A2 (fr)
CR (1) CR20120042A (fr)
EC (1) ECSP12011685A (fr)
ES (1) ES2534085T3 (fr)
IL (1) IL217844A0 (fr)
MA (1) MA33717B1 (fr)
MX (1) MX2012002014A (fr)
PE (1) PE20120630A1 (fr)
RU (1) RU2583876C2 (fr)
SG (1) SG178443A1 (fr)
TW (1) TW201119672A (fr)
WO (1) WO2011020783A2 (fr)
ZA (1) ZA201200767B (fr)

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5992710A (ja) * 1982-11-16 1984-05-29 関西電力株式会社 直接水冷線路の立坑部の布設方法
WO2011040973A2 (fr) * 2009-10-02 2011-04-07 Ludwig Institute For Cancer Research Ltd. Immunoconjugués de tnf avec des anticorps de protéine d'activation des fibroblastes et procédés et utilisations de ceux-ci
AU2015213405B2 (en) * 2010-08-13 2017-08-03 Roche Glycart Ag Anti-FAP antibodies and methods of use
BR112013002444A2 (pt) 2010-08-13 2016-05-24 Roche Glycart Ag anticorpo, polinucleotídeo e polipeotídeo isolados, composição, vetor, cécula hospedeira, conjulgado de anticorpo, formulação farmacêutica, uso do anticorpo, métodos para produzir um anticorpo, tratar um indivíduo, induzir a lise celular de uma célula tumorosa e diagnosticar uma doença em um indivíduo
PE20171512A1 (es) * 2010-08-13 2017-10-20 Roche Glycart Ag Anticuerpos anti-fap
RU2013139267A (ru) * 2011-02-10 2015-03-20 Рош Гликарт Аг Улучшенная иммунотерапия
CN105440123B (zh) 2011-02-10 2020-10-09 罗切格利卡特公司 突变体白介素-2多肽
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
JP2014534806A (ja) 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
ES2762179T3 (es) * 2011-09-26 2020-05-22 Philogen Spa Terapia de combinación de inmunocitocinas
WO2013107791A1 (fr) 2012-01-20 2013-07-25 Vib Vzw Cytokines en faisceau à hélices alpha mutantes à cible spécifique
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
PL3434695T3 (pl) * 2012-08-07 2021-05-17 Roche Glycart Ag Ulepszona immunoterapia
US9346872B2 (en) 2012-08-08 2016-05-24 Roche Glycart Ag Interleukin-10 fusion proteins
WO2014023709A1 (fr) 2012-08-09 2014-02-13 Roche Glycart Ag Anticorps asgpr et leurs utilisations
WO2014043523A1 (fr) 2012-09-14 2014-03-20 The Johns Hopkins University Compositions et procédés pour rendre des cellules tumorales sensibles à la destruction à médiation par des lymphocytes t cd8+
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
WO2014172448A2 (fr) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Anticorps diriges contre le recepteur d'activine de type ii (actrii)
KR102322510B1 (ko) 2013-07-18 2021-11-08 브이아이비 브이지더블유 수용체 결합친화성이 현격히 감소된 사이토카인을 수반하는 푸소카인
CA2918518C (fr) * 2013-07-19 2022-08-16 Universiteit Gent Membres de la famille il-1 modifies cibles
US9732135B2 (en) 2013-07-19 2017-08-15 Vib Vzw Targeting of human interferon antagonists
MX370565B (es) 2013-07-19 2019-12-17 Vib Vzw Miembros de la familia tnf modificados dirigidos.
EP3738594A1 (fr) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques ciblés ayant un ligand hsp90 comme moietie de liaison
WO2015066053A2 (fr) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Thérapies ciblées
EP3099332A4 (fr) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Agents thérapeutiques cibles
JP6576942B6 (ja) * 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
WO2015168474A1 (fr) * 2014-04-30 2015-11-05 President And Fellows Of Harvard College Protéines de fusion pour le traitement du cancer et procédés associés
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
GB201500875D0 (en) * 2015-01-19 2015-03-04 Philogen Spa Antibodies for treatment and diagnosis
SG11201706562QA (en) * 2015-02-13 2017-09-28 Agency Science Tech & Res NON-MEMBRANE DISRUPTIVE p53 ACTIVATING STAPLED PEPTIDES
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
JP6996979B2 (ja) * 2015-03-31 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 三量体ｔｎｆファミリーリガンドを含む抗原結合分子
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
EP3371311B1 (fr) 2015-11-06 2021-07-21 Orionis Biosciences BV Protéines chimères bifonctionnelles et leurs utilisations
US10144768B2 (en) 2015-12-04 2018-12-04 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
CN106349393B (zh) * 2015-12-21 2020-10-30 合肥立方制药股份有限公司 一种增强抗体药物稳定性的结构
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
WO2017194783A1 (fr) 2016-05-13 2017-11-16 Orionis Biosciences Nv Interféron bêta mutant ciblé, et utilisations associées
EP3455245A2 (fr) * 2016-05-13 2019-03-20 Orionis Biosciences NV Ciblage thérapeutique de structures non cellulaires
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
EP3511340B1 (fr) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Hétérodimère fc-fusionné cytokine et composition pharmaceutique le comprenant
CA3037682A1 (fr) 2016-09-21 2018-03-29 The Wistar Institute Of Anatomy And Biology Compositions immunogenes consensus synthetiques optimisees ciblant la proteine d'activation des fibroblastes
IL310865A (en) 2016-10-17 2024-04-01 Pfizer Antibodies against EDB and antibody-drug conjugates
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
WO2018083248A1 (fr) 2016-11-03 2018-05-11 Kymab Limited Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
CA3041279A1 (fr) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Domaine de liaison a l'antigene et polypeptide comprenant une section de transport
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
JP7125400B2 (ja) * 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
CN108250302A (zh) * 2016-12-29 2018-07-06 天津天锐生物科技有限公司 一种多功能蛋白质
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
EP3576765B1 (fr) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Interféron d'ingénierie ciblé et utilisations de ce dernier
CA3050601A1 (fr) 2017-02-07 2018-08-16 Vib Vzm Proteines chimeres bispecifiques ciblees par des cellules immunitaires, et utilisations associees
KR102461885B1 (ko) 2017-04-03 2022-11-03 에프. 호프만-라 로슈 아게 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
JP7148539B2 (ja) 2017-04-03 2022-10-05 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 免疫抱合体
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
KR102920712B1 (ko) 2017-05-24 2026-01-30 노파르티스 아게 항체-사이토카인 생착된 단백질 및 암 치료에 있어서의 사용 방법
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
US11377447B2 (en) 2017-06-20 2022-07-05 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
US11491145B2 (en) 2017-06-20 2022-11-08 Madrigal Pharmaceuticals, Inc. Combination therapies comprising targeted therapeutics
CN118126157A (zh) 2017-08-03 2024-06-04 美国安进公司 白介素-21突变蛋白和治疗方法
CN117924493A (zh) 2017-08-09 2024-04-26 奥里尼斯生物科学有限公司 Clec9a结合剂及其用途
EP3664829A4 (fr) 2017-08-09 2021-05-05 Orionis Biosciences, Inc. Agents de liaison à pd-1 et pd-l1
EP3665201A4 (fr) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. Agents de liaison au cd8
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
TWI844524B (zh) * 2018-02-09 2024-06-11 義大利商費洛根公司 靶向edb之il-12組合物
EP3765517A1 (fr) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Molécules multifonctionnelles se liant à calréticuline et utilisations associees
SG11202011139YA (en) * 2018-05-16 2020-12-30 Dragonfly Therapeutics Inc Protein binding nkg2d, cd16 and a fibroblast activation protein
EP3807312A4 (fr) 2018-05-30 2022-07-20 Chugai Seiyaku Kabushiki Kaisha Polypeptide comprenant un domaine de liaison à l'aggrécane et une fraction de transport
WO2020010250A2 (fr) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
JP2021532796A (ja) * 2018-07-30 2021-12-02 晋宇 張 タンパク質ヘテロ二量体およびその使用
EP3833391A4 (fr) 2018-08-08 2022-08-10 Orionis Biosciences, Inc. PROTÉINES CHIMÈRES CIBLÉES SUR SIRP1alpha ET LEURS UTILISATIONS
WO2020051363A1 (fr) * 2018-09-07 2020-03-12 Nantbio, Inc. Traitements ciblés à base d'il-12 et méthodes de stimulation des cellules hank et nk92mi
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
EP3890773A4 (fr) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. Modulation de lignées de cellules dendritiques
RU2708558C1 (ru) * 2018-12-13 2019-12-09 Российская Федерация, от имени которой выступает ФОНД ПЕРСПЕКТИВНЫХ ИССЛЕДОВАНИЙ Способ создания противоопухолевой иммунологической защиты к клеткам лимфомы EL-4
JP7579795B2 (ja) 2019-02-21 2024-11-08 マレンゴ・セラピューティクス，インコーポレーテッド ＮＫｐ３０に結合する抗体分子およびその使用
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
CN113840833B (zh) 2019-03-28 2025-06-17 奥里尼斯生物科学股份有限公司 基于clec9a的嵌合蛋白复合物
AU2020285636A1 (en) * 2019-05-24 2021-11-04 Proviva Therapeutics (Hong Kong) Limited IL-2 compositions and methods of use thereof
JP7778571B2 (ja) * 2019-06-05 2025-12-02 アッシャー バイオセラピューティクス， インコーポレイテッド 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
EP3981428A4 (fr) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Substrat de protéase et polypeptide comprenant une séquence de clivage de protéase
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
JP2022538139A (ja) 2019-07-02 2022-08-31 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 変異体インターロイキン－２及び抗ｃｄ８抗体を含む免疫複合体
TW202120537A (zh) 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法
CA3163358A1 (fr) 2019-12-03 2021-06-10 Evotec International Gmbh Proteines de liaison a l'antigene associees a l'interferon et leurs utilisations
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
WO2021138474A2 (fr) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Molécules d'anticorps anti-tcr et leurs utilisations
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
CA3171795A1 (fr) * 2020-04-06 2021-10-14 Jintang DU Recepteurs de synthese modulaires et leurs methodes d'utilisation
CA3168460A1 (fr) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugues
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
KR102799318B1 (ko) * 2020-08-11 2025-04-23 주식회사 카나프테라퓨틱스 Il-12 및 항-fap 항체를 포함하는 융합단백질 및 이의 용도
KR20230117122A (ko) 2020-12-04 2023-08-07 에프. 호프만-라 로슈 아게 pH 의존성 돌연변이체 인터류킨-2 폴리펩티드
WO2022148853A1 (fr) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugués
JP2024513651A (ja) 2021-02-26 2024-03-27 ニューヨーク ユニバーシティ 共有結合性ペプチドコンジュゲートに結合する抗体を含む組成物及び方法
CN117015555A (zh) 2021-03-09 2023-11-07 豪夫迈·罗氏有限公司 Pd-1靶向il-2变体免疫缀合物和抗tyrp1/抗cd3双特异性抗体的组合疗法
AU2022231874A1 (en) 2021-03-09 2023-07-27 F. Hoffmann-La Roche Ag Combination therapy of pd-1-targeted il-2 variant immunoconjugates and fap/4-1bb binding molecules
TW202317623A (zh) 2021-06-14 2023-05-01 美商再生元醫藥公司 基於il2之治療劑及其使用方法
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.
EP4429706A1 (fr) 2021-10-14 2024-09-18 F. Hoffmann-La Roche AG Immunoconjugués de pd1-il7v alternatifs pour le traitement du cancer
PE20241627A1 (es) 2021-10-14 2024-08-07 Hoffmann La Roche Nuevos inmunoconjugados de interleucina-7
CN118284625A (zh) 2021-11-26 2024-07-02 豪夫迈·罗氏有限公司 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
US20250073239A1 (en) * 2022-01-04 2025-03-06 Philogen S.P.A. Combination of an immunocytokine comprising il-12 and a kinase inhibitor
WO2024153722A1 (fr) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Immunoconjugués
WO2025202147A1 (fr) 2024-03-27 2025-10-02 F. Hoffmann-La Roche Ag Immunoconjugués d'interleukine-7
WO2025233304A1 (fr) 2024-05-08 2025-11-13 F. Hoffmann-La Roche Ag Polypeptides de variants de domaine fc-il-7 recombinants et polythérapie avec des polypeptides de liaison à l'antigène à ancrage membranaire
WO2026104323A1 (fr) 2024-11-12 2026-05-21 F. Hoffmann-La Roche Ag Immunoconjugués flt3l ciblés et méthodes d'utilisation
WO2026104336A1 (fr) 2024-11-13 2026-05-21 F. Hoffmann-La Roche Ag Immunoconjugués

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CA2284079C (fr) * 1997-03-05 2009-05-12 David M. Neville Nouvelles immunotoxines et nouveaux procedes d'induction de tolerance immunitaire
ES2221717T3 (es) * 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US8623373B2 (en) 2000-02-24 2014-01-07 Philogen S.P.A. Compositions and methods for treatment of angiogenesis in pathological lesions
WO2001075110A2 (fr) * 2000-03-30 2001-10-11 Dyax Corp. Elements de liaison specifiques de la mucine-1 et techniques d'utilisation
CZ2003214A3 (cs) * 2000-06-29 2003-08-13 Merck Patent Gmbh Zesílení odpovědi mediovaných fúzním proteinem protilátka-cytokin kombinovanou léčbou pomocí činidel zvyšujících uptake imunocytokinu
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US8491896B2 (en) * 2002-06-14 2013-07-23 Immunomedics, Inc. Anti-pancreatic cancer antibodies
BRPI0608468A2 (pt) 2005-03-25 2010-01-05 Glycart Biotechnology Ag moléculas de ligação a antìgeno direcionadas a mcsp e tendo afinidade de ligação a receptor de fc e função efetora aumentadas
MX2007013875A (es) * 2005-05-11 2008-01-28 Philogen Spa Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12.
US8744844B2 (en) * 2007-07-06 2014-06-03 Audience, Inc. System and method for adaptive intelligent noise suppression
JP2009536170A (ja) 2006-05-08 2009-10-08 フィロジェン・エッセペア 治療用の抗体標的指向サイトカイン
US9364557B2 (en) * 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物

Also Published As

Publication number Publication date
US8945571B2 (en) 2015-02-03
US20110064751A1 (en) 2011-03-17
RU2012110127A (ru) 2013-09-27
CA2769619C (fr) 2019-04-30
EP2467165B1 (fr) 2015-01-07
RU2583876C2 (ru) 2016-05-10
IL217844A0 (en) 2012-03-29
PE20120630A1 (es) 2012-05-26
TW201119672A (en) 2011-06-16
JP2013502209A (ja) 2013-01-24
SG178443A1 (en) 2012-04-27
AR077879A1 (es) 2011-09-28
CN102573922A (zh) 2012-07-11
CO6430436A2 (es) 2012-04-30
CN102573922B (zh) 2015-08-05
AU2010285071A1 (en) 2012-02-02
KR20120053042A (ko) 2012-05-24
CR20120042A (es) 2012-03-22
KR101588598B1 (ko) 2016-01-29
CA2769619A1 (fr) 2011-02-24
WO2011020783A2 (fr) 2011-02-24
ECSP12011685A (es) 2012-03-30
KR20150088328A (ko) 2015-07-31
WO2011020783A3 (fr) 2011-04-28
ES2534085T3 (es) 2015-04-17
EP2467165A2 (fr) 2012-06-27
MX2012002014A (es) 2012-06-13
ZA201200767B (en) 2014-07-30
HK1169318A1 (zh) 2013-01-25
JP5764127B2 (ja) 2015-08-12

Similar Documents

Publication Publication Date Title
MX2009005849A (es) Composiciones y metodos para tratar cancer con adn rico en cpg y cupredoxinas.
WO2007042261A3 (fr) Compositions comportant des anticorps specifiques d'especes croisees et leurs utilisations
WO2008060367A3 (fr) Anticorps humains qui se lient au cxcr4, et leurs utilisations
WO2008076560A3 (fr) Anticorps monoclonaux humains contre le btla et procédés d'utilisation
WO2006076691A3 (fr) Anticorps 2 associes a la translocation de recepteur immunitaire (irta-2) et leurs utilisations
MX2008009886A (es) Anticuerpos que enlazan par-2.
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
MA34053B1 (fr) Polypeptides agonistes de liaison à dr5
BRPI0510617A (pt) uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2005016946A3 (fr) Complexes de platine et procedes d'utilisation
MX2007001638A (es) Proteinas de fusion del dominio de unión.
WO2005097185A3 (fr) Anticorps irta-5 et utilisations de ces derniers
WO2011020783A3 (fr) Immunoconjugués ciblés
WO2008136848A3 (fr) Nouveaux anticorps anti-notch3 et leur utilisation dans la détection et le diagnostic d'une maladie
WO2008108830A3 (fr) Compositions immunogènes et thérapeutiques pour streptococcus pyogenes
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
WO2008085962A3 (fr) Méthodes de culture cellulaire destinées à la production de protéines recombinées en présence de niveaux réduits d'un ou plusieurs contaminants
WO2010072740A3 (fr) Agents de liaison ciblés dirigés contre α5β1 et leurs applications
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2004108065A3 (fr) Activite d'heparanase neutralisant un anticorps monoclonal anti-heparanase et d'autres anticorps anti-heparanase
WO2006091861A8 (fr) Compositions et methodes associees au lymphome du systeme nerveux central